Jeffrey M. Leiden - Feb 1, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Executive Chairman, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 1, 2023
Transactions value $
-$1,137,196
Form type
4
Date filed
2/3/2023, 03:53 PM
Previous filing
Jul 27, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +31.5K +1298.47% $0.00 33.9K Feb 1, 2023 Direct F1
transaction VRTX Common Stock Award $0 +34.9K +102.97% $0.00 68.8K Feb 1, 2023 Direct F2
transaction VRTX Common Stock Award $0 +10.2K +14.87% $0.00 79K Feb 1, 2023 Direct F3
transaction VRTX Common Stock Tax liability -$1.14M -3.58K -4.53% $317.83 75.4K Feb 2, 2023 Direct
holding VRTX Common Stock 440 Feb 1, 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/24/2023.
F3 Restricted stock unit award that fully vested upon grant.